Research
Hormonal
Incretin mimetics, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists, are first-line treatment options for type 2 diabetes and obesity.
Healthcare professionals should consider these agents as primary treatment options for managing type 2 diabetes and obesity.
StrongSupportsmedium confidence
Incretin mimetics, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists, have become first-line treatment options for the treatment of type 2 diabetes and obesity.
Why this rating
The claim is based on a narrative review of current literature.
Source
Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review
Jason Zupec et al. · Nutrition in Clinical Practice · 2025
reviewCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →